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Abstract
Beta-amyloid (Aβ) deposition in brain accumulates as a function of age in people with Down 
syndrome (DS) with subsequent development into Alzheimer disease neuropathology, typically by 
40 years of age. In vivo imaging using the Pittsburgh Compound B (PiB) ligand has facilitated 
studies linking Aβ, cognition, and dementia in DS. However, there are no studies of PiB binding 
across the lifespan in DS. The current study describes in vitro 3H-PiB binding in the frontal cortex 
of autopsy cases with DS compared to non-DS controls. Tissue from 64 cases included controls 
(N=25) and DS (N=39). In DS, 3H-PiB binding was significantly associated with age. After age 40 
years in DS, 3H-PiB binding rose dramatically along with increasing individual variability. 3H-PiB 
binding correlated with the amount of Aβ42. Using fixed frontal tissue and fluorescent 6-CN-PiB, 
neuritic and cored plaques along with extensive cerebral amyloid angiopathy (CAA) showed 6-
CN-PiB binding. These results suggest that cortical PiB binding as shown by positron emission 
tomography imaging reflects plaques and CAA in DS brain.
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1. Introduction
Alzheimer disease (AD) is the most common cause of dementia in the elderly and affects 1 
in 9 people over the age of 65 years (http://www.alz.org/facts/). There are currently no 
biomarkers for AD that can clearly distinguish people who will develop the disease from 
those who will not. The presence of beta-amyloid (Aβ) plaques and tau neurofibrillary 
tangles determined at autopsy are defining characteristics for a pathological diagnosis of 
AD. However, the development of in vivo ligands that selectively bind to Aβ, allows these 
lesions to be visualized and quantified in people using positron emission tomography (PET), 
significantly accelerating biomarker development (Cohen and Klunk, 2014;Johnson, et al., 
2012;Mintun, et al., 2006;Sperling, et al., 2014). The first of these ligands, Pittsburgh 
Compound B (PiB) (Klunk, et al., 2004) has now been used in a large number of clinical 
studies in patients with AD and can detect Aβ plaques in early disease (Cohen and Klunk, 
2014).
3H-PiB and 6-CN-PiB binding in vitro has been described in autopsy cases of AD in the 
general population (Bacskai, et al., 2007;Beckett, et al., 2012;Ikonomovic, et al., 
2012;Ikonomovic, et al., 2008;Klunk, et al., 2007). Aβ40 and Aβ42 positive plaques as well 
as vascular Aβ bind PiB in vitro. PiB binding was more robust in compact or cored plaques 
and less so with diffuse plaques. Typically neurofibrillary tangles did not bind PiB except for 
possible weak binding to extracellular “ghost” tangles, which may be due to associated Aβ 
(Ikonomovic, et al., 2008). Finally, PiB binding correlates early in disease with postmortem 
insoluble Aβ measures and with plaque loads. In one case that was PET imaged in life with 
PiB and then came to autopsy, there was a significant overlap in the regional distribution of 
the in vivo plaque binding and in vitro PiB binding (Bacskai, et al., 2007).
Down syndrome (DS) or trisomy 21, is the most common genetic cause of intellectual 
disability and is associated with a neurologic phenotype that includes the development of 
AD neuropathology by the age of 40 years (Head, et al., 2016;Lott, 2012;Lott and Dierssen, 
2010). Further, autopsy studies indicate that in DS there is an age-associated progression of 
AD neuropathology with initial deposits of Aβ and subsequent formation of neurofibrillary 
tangles (Head, et al., 2016;Hof, et al., 1995;Leverenz, 1998;Wisniewski, et al., 1985). Even 
so, the age of onset of dementia may be delayed by almost a decade (over 50 years of age) 
after AD neuropathology is present and a subset of people with DS appear to not develop 
dementia even at very old ages (Lai, 1989;Schupf, 2002).
PiB PET imaging studies in people with DS show that binding is age-dependent (Annus, et 
al., 2016;Handen, et al., 2012;Hartley, et al., 2014;Landt, et al., 2011;Lao, et al., 2016). Two 
of these studies included measures of impaired cognition and dementia status and found a 
positive significant correlation with PiB load (Annus, et al., 2016;Hartley, et al., 2014). 
Striatal PiB is the earliest site of binding with age in DS, typically observed after 35 years of 
age (Annus, et al., 2016;Handen, et al., 2012;Lao, et al., 2016) and is similar to reports of 
patients with presenilin-1 mutations (Klunk, et al., 2007;Koivunen, et al., 2008;Villemagne, 
et al., 2009). Subsequently, with increasing age, more brain regions become affected 
including the neocortex (Annus, et al., 2016).
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The age-dependency of PiB binding in DS in vivo may be a biomarker for AD 
neuropathology that can be used as an outcome measure in clinical trials. We hypothesized 
that 3H-PiB binding would increase as a function of age in DS in frontal cortex. Thus, we 
measured 3H-PiB binding biochemically in frontal cortex homogenates from autopsy cases 
with and without DS. We used the highly fluorescent PiB derivative, 6-CN-PiB, which has 
similar binding properties as PiB (Ikonomovic, et al., 2008;Mathis, et al., 2003) in fixed 
tissue to visualize plaques and, if present, cerebral amyloid angiopathy (CAA) to determine 
what types of pathology PiB binding represents in vivo.
2. Materials and methods
2.1 Autopsy cases
Frozen frontal cortex (Brodmann area 46) was obtained from 64 cases in total from the 
University of Kentucky Alzheimer Disease Center, the Alzheimer Disease Research Center 
at the University of California at Irvine, and the NIH NeuroBioBank. Human tissue 
collection and handling conformed to each University’s Institutional Review Board 
guidelines.
Cases ranged from 1 to 66 years of age (Table 1). Control cases were selected to match for 
age and postmortem interval (PMI) to match the DS cases. Both males and females were 
included in the study, but given the challenges of matching cases, we did not match for 
gender. The level of premorbid intellectual disability or cognitive status was not available in 
most cases and thus it was not possible to use these variables in the analysis.
The PMI was different across groups, with the control cases showing an overall longer PMI 
(t(62)=3.0 p=.004) relative to DS cases. Correlation co-efficients were thus adjusted for PMI 
when necessary.
2.2 3H-PiB binding
3H-PiB binding was used to measure fibrillar Aβ and was assessed in homogenates of 
frontal cortex (Beckett, et al., 2012;Matveev, et al., 2014). Instead of the 10 μM 
concentrations typically used for histological assay, which will also bind to low affinity sites, 
we used 1.2 nM PiB, a concentration closer to the Kd of the PiB analog CN-PiB for Aβ 
pathology and to the in vivo concentration of 11C-PiB used to visualize high affinity PiB 
binding in human AD brain. For binding studies, 20 μL of a PBS homogenate containing 
0.166 mg wet weight tissue were added to each of three wells of a 96-well polypropylene 
plate (Costar 3365). 200 μL of 1.2 nM 3H-PiB (cat. VT 278 specific radioactivity = 70.2 Ci/
mmol, Vitrax [Placentia, CA]) in PBS + 5% v/v EtOH was added to two of the wells (total 
binding) and to the third well 200 μL of 1.2 nM 3H-PiB + 1 μM unlabeled competitor BTA-1 
(non-specific binding) was added. The plate was sealed with plastic film. Samples were 
incubated for 2 hours at room temperature without shaking, transferred to a 96-well 
Millipore Multiscreen HTS Hi Flow FB (GF/B) filter plate, and filtered on a multi-well plate 
vacuum manifold (Millipore Corporation, Bedford, MA). The filters were washed three 
times with 200 μL of PBS + 5% v/v EtOH, dried, removed from the plate, and placed in 
scintillation vials with 2 mL of BudgetSolve scintillation fluid and counted for 3H. Specific 
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binding for each sample was calculated as total binding (mean CPM of the two filters from 
wells containing radioactive PiB) minus non-specific binding (CPM value from the well 
containing radioactive PiB + 1 μM nonradioactive BTA-1 competitor).
2.3 3H-X-34 binding
3H-X-34 binding (Matveev, et al., 2014) was used to measure a combination of fibrillar Aβ 
and neurofibrillary tangles and was performed with 10 μl of a PBS homogenate containing 
0.166 mg wet weight tissue similar to 3H-PiB binding, with 5 nM 3H-X-34, 23 Ci/mmol, 
custom titrated by Vitrax) (Matveev, et al., 2014) with 10 μM Congo Red as the 
nonradioactive X-34 competitor.
2.4 Aβ ELISA
To measure total soluble and insoluble Aβ40 and Aβ42 in frontal cortex, we used an ELISA. 
The methods for tissue extraction and Aβ measurements have been published previously 
(Beckett, et al., 2010). Briefly, frozen cortical samples were serially extracted to obtain 
fractions of different assembly states of Aβ. The tissue was homogenized in a Dounce 
homogenizer in ice cold phosphate buffered saline (PBS, pH 7.4) containing 1× complete 
protease inhibitor cocktail (PIC) (Amresco, Solon, OH), and centrifuged at 20,800 × g for 30 
minutes at 4°C. Following centrifugation, the supernatant was collected for subsequent 
measures of PBS soluble Aβ and the pellets were sonicated (10 × 0.5 sec pulses at 100W, 
Fisher Sonic Dismembrator) in room temperature 2% SDS in PBS with PIC followed by 
centrifugation (as above, but at 14°C). The supernatant was again collected to measure SDS 
soluble Aβ, and the remaining pellets were sonicated in 70% formic acid (FA) followed by 
centrifugation at 20,800 × g for 1 hour at 4°C. The supernatant collected was used to 
measure insoluble Aβ. Aβ was measured in these extracts using a standard, well-
characterized two-site sandwich ELISA as described previously [47]. Briefly, an Immulon 
4HBX plate (Dynex-Thermo Fisher) was coated with 0.5 μg/well of antibody, incubated 
overnight at 4° C, then blocked with a solution of Synblock (AbD Serotec, Raleigh, NC), as 
per the manufacturer’s instructions. Antigen capture was performed using monoclonal 
antibody Ab9 (against Human Aβ(1–16)). Antigen detection was performed using 
biotinylated antibodies 13.1.1. (end specific for Aβ(x-40)), and 12F4 (end specific for 
Aβ(x-42); Covance, Princeton, NJ).
To measure insoluble Aβ, formic acid-soluble supernatant was initially neutralized by a 1:20 
dilution in TP buffer (1 M Tris base, 0.5 M Na2HPO4), followed by a further dilution as 
needed (1:100 to 1:400) in Antigen Capture buffer (AC) (0.02 M sodium phosphate buffer, 
0.4 M NaCl, 2mM EDTA, 0.4% Block Ace (AbD Serotec), 0.05% NaN3, 0.2% BSA, 0.05% 
CHAPS, pH 7). SDS-soluble fractions were diluted (1:20) in AC buffer alone and PBS 
fractions were diluted 1:4 in AC buffer alone. A peptide standard curve of Aβ was run on the 
same plate for comparison, and standards and samples were run at least in duplicate; Aβ 
values were determined by interpolation relative to the standard curve. Plates were washed 
2–4 times between assay steps with standard PBS containing 0.05% Tween-20 (2–4×) 
followed by PBS (2–4×). Plates were developed with TMB reagent (Kirkegaard & Perry 
Laboratories, Gaithersburg, MD), stopped with 6% o-phosphoric acid, and read at 450 nm 
using a BioTek multiwell plate reader.
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2.5 CN-PiB binding in vitro and comparison to AD neuropathology
To visually characterize plaque and vascular binding of PiB in vitro, we used fixed tissue 
sections from the frontal cortex of two control cases (19 years and 51.3 years), DS (19.8 
years), and DS with AD (DSAD) case (51.4 years) and the fluorescent cyano-PiB (CN-PiB). 
Sections were first mounted on slides and allowed to dry prior to incubation in 100 nM CN-
PiB for 1 hour at RT using a similar protocol as published previously (Ikonomovic, et al., 
2008) but at a lower concentration closer to the CN-PiB Kd to focus on high affinity imaging 
ligand-relevant binding. Slides were washed in PBS for 3× for 2 minutes then incubated 
briefly (30s) in TrueBlack™ lipofuscin autofluorescence quencher (Biotium, Hayward, CA). 
After three more 2-minute washes in PBS, slides were coverslipped using Everbrite™ 
mounting media (Biotium). Images were captured using an Olympus BX51 microscope with 
a Q Color 5 digital camera. A second set of sections was first incubated in CN-PiB as 
described above but prior to Trueblack quenching for autofluorescence, slides were 
incubated in 0.5% thioflavine-S (Sigma-Aldrich, St. Louis, MO) in 50% ethanol, 
differentiated in 50% ethanol, washed, and then exposed to TrueBlack. Sections were 
coverslipped using Everbrite™.
2.6 Statistical analysis
SPSS for Windows and independent t-tests were used to test for PMI differences across the 2 
groups (Control, DS). A stepwise linear regression was used to determine which outcome 
measure best predicted age in DS cases. Spearman rank correlations were used to measure 
the strength of association between specific 3H-PiB binding, 3H-X-34 binding, and age in 
DS.
3. Results
3.13H-PiB binding
We tested the hypothesis that specific 3H-PiB binding levels would vary as a function of age 
in DS. Fig. 1A shows a significant association between age at death in DS autopsy cases and 
the amount of 3H-PiB binding that was not linear but rather increased dramatically in cases 
over 40 years of age. A significant Spearman rank correlation between specific 3H-PiB 
binding and age in DS was observed (r=0.54 p<0.0005 n=39), which remained after 
controlling for PMI (r=0.35 p<0.03) but not in controls (selected to be pathology free). 
Additional individual variability may be due to the presence or severity of dementia, 
however these data were not available for this study.
3.2 3H-X-34 binding
We next tested the hypothesis that the highly-fluorescent Congo Red derivative, 3H-X-34, 
which binds to a site on amyloid fibrils in plaques and neurofibrillary tangles and that is 
distinct from the 3H-PiB binding site, would also vary with age in cases with DS. As 
with 3H-PiB binding, we observed a significant increase in specific 3H-X-34 binding and 
age of death (r=0.58 p<.0005 n=39) in DS (but not controls, selected to be pathology free) 
(Fig.1B). However, this correlation was reduced with the inclusion of PMI when calculating 
a partial correlation co-efficient (r=0.29 p=0.08).
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Predicting 3H-PiB and 3H-X-34 binding—Two independent stepwise linear regressions 
were used to determine the best predictor of specific 3H-PiB or 3H-X-34 binding with PBS 
soluble oligomers, PBS, SDS, and FA Aβ40 and Aβ42 levels included in the analysis. The 
SDS Aβ42 fraction, the amount of oligomers, and the FA fraction of Aβ42 predicted 
specific 3H-PiB binding (Table 2). In contrast, 3H-X-34 binding was best predicted by PBS 
oligomers and the two FA fractions (Aβx-40 and Aβx-42) (Table 2). 3H-X-34 also binds to 
neurofibrillary tangles, which were not systematically measured in the current study. 
Interestingly, of all the measures that predict age in the DS autopsy series, specific 3H-PiB 
binding was the best, not oligomers or Aβ measures (r=0.50, F(1,38)=12.47 p=0.001).
3.5 6-CN-PiB labeling in frontal cortex of DS and control cases
6-CN-PiB binding was not present at detectable levels in control cases (Fig. 2A and B) and 
in a young case with DS (Fig.2C). The DSAD case showed significant amounts of 6-CN-PiB 
labeling of plaques (Fig. 2D). In addition, substantial 6-CN-PiB binding to the vasculature 
was observed in DSAD, consistent with CAA. Double label studies with thioflavine S 
clearly show that 6-CN-PiB does not bind to neurofibrillary tangles in DSAD brain (Fig. 
3A). Thioflavine S binds to the same site as Congo Red and 3H-X-34 and does not disturb 6-
CN-PiB binding. At higher magnification, 6-CN-PiB appears to bind to neuritic plaques 
(Fig.3B). Further, 6-CN-PiB binds to the cores of plaques as thick fibrils with a halo of 
thioflavine S-positive amyloid fibers on the periphery (Fig. 3C).
4. Discussion
The current study describes age-associated high affinity specific 3H-PiB and 3H-X-34 
binding in autopsy cases with DS, which expands existing PiB PET studies in vivo in people 
with DS to now include a broad range of ages from 1 to 66 years. Instead of the 10 μM 
concentrations of ligand used for histology, which will also bind to low affinity sites, we use 
100 nM CN-PiB, a concentration closer to the Kd of CN-PiB for Aβ pathology and to the in 
vivo concentration of 11C-PiB used to visualize high affinity CN-PiB binding in human AD 
brain. In DS, 3H-PiB binding increases rapidly after 40 years of age with variability between 
individuals also increasing with age. 3H-PiB binding in DS appears to be best correlated 
with Aβ42 levels (SDS and FA soluble) rather than Aβ40 peptide levels based on regression 
analyses. 6-CN-PiB binding in autopsy cases shows a preference for fibrillar, cored, and 
neuritic plaques along with CAA with no binding at these low concentrations to intracellular 
neurofibrillary tangles (Ikonomovic, et al., 2008).
In the first report of autopsy correlates of 11C-PiB binding in vivo in sporadic AD, Bacskai 
and colleagues showed overlap in immunostaining for Aβ and 11C-PiB binding in vitro, 
including CAA (Bacskai, et al., 2007). Several studies now report 11C-PiB binding in 
autopsy cases showing that in vitro binding to tissue sections, PiB binds to neuritic plaques 
and weakly to diffuse plaques. Strong binding is observed in CAA and in some cases 
labeling of extracellular tangles (Ikonomovic, et al., 2012;Ikonomovic, et al., 2008;Klunk, et 
al., 2007). In a study of a PET 11C-PiB negative patient with mild cognitive impairment at 
the time of the PET scan, but elevated CSF tau and reduced CSF Aβ, numerous diffuse Aβ 
plaques and CAA were observed at autopsy suggesting either that there was insufficient 
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fibrillar Aβ to bind PiB in vivo (Cairns, et al., 2009) or that not all fibrillar forms of Aβ bind 
to 11C-PiB. In a series of 6 older autopsy cases with PET 11C-PiB imaging, there was a 
positive correlation between Aβ plaque counts and extent of PiB binding (Driscoll, et al., 
2012). Results from the current study also suggest that 3H-PiB binding in vitro in DS frontal 
cortex is associated with neuritic plaques and CAA with weak or no labeling of diffuse 
plaques in DS in the small set of cases we could examine. Thus, consistent with studies in 
sporadic AD and in non-DS autopsy cases, it may also be the case that 6-CN-PiB binds only 
a subset of Aβ deposits but not those within diffuse deposits in DS. Autopsy studies suggest 
that diffuse plaques in DS appear prior to neuritic plaques (prior to 40 years of age) (Head, 
et al., 2016) but PET PiB studies show a later age of onset of binding than that observed at 
autopsy. In combination, these results may indicate that weak PiB binding precludes diffuse 
plaque visualization by PET imaging. However, higher concentrations of CN-PiB in vitro 
may allow it to bind to diffuse plaques in autopsy tissue and assessing more cases between 
20–40 years of age will be helpful in future to establish this possible outcome.
In the current study, we show a broad range in 3H-PiB binding in the frontal DS cortex that 
is strongly age-associated. In addition, by the inclusion of multiple measures of soluble and 
insoluble Aβ40 and Aβ42 as well as oligomers, regression analyses show that SDS soluble 
Aβ42 was the strongest predictor of PiB binding in DS but including the amount of 
oligomers and insoluble Aβ42 improved the prediction of PiB binding. Our study confirms 
and extends previous biochemical measures of PiB binding in autopsy tissue that suggest 
binding in vivo by PET imaging is associated with the presence of insoluble Aβ (Kadir, et 
al., 2011). Studies in autopsy tissue from the frontal cortex and hippocampus show 
significantly higher amounts of PiB binding in clinically characterized AD cases compared 
with age-matched clinically normal controls, although there can be some overlap (Ni, et al., 
2013). Further, total Aβ40 and Aβ42 measured by ELISA also correlates with PiB binding 
in vitro in a case series of 5 AD and 5 control brains (Ni, et al., 2013). In a large case series 
that included controls, preclinical AD, and AD samples, PiB binding correlated with 
oligomeric Aβ, SDS soluble Aβ, and FA soluble Aβ (Beckett, et al., 2012).
The age-dependency of our biochemical measures of PiB binding in frontal cortex in DS 
cases suggests a dramatic increase in PiB binding after the age of 40 years, which parallels 
age-associated increases in insoluble Aβ42 (Cenini, et al., 2012). Previous studies of PiB 
imaging in people with DS have included volunteers from 25 years and older and we now 
provide data from autopsy samples as young as one year of age. Our in vitro binding assay 
data are consistent with PET 11C-PiB imaging studies in people with DS typically showing 
positive binding in cortex in participants over the age of 35 years (Annus, et al., 
2016;Handen, et al., 2012;Hartley, et al., 2014;Landt, et al., 2011;Lao, et al., 2016). 
However, a caveat with our study is that we have a gap in DS autopsy cases when Aβ 
typically begins to accumulate (25–40 years). This can be a challenge with DS autopsy 
studies that are limited by the number of cases available. Further, we are not able to 
determine if clinical status may be a better predictor of 3H-PiB binding in vitro given that 
these data were not available on the current cases. Further, there as of yet is no consensus on 
how best to characterize severity of dementia in people with DS as standardized tests such as 
the MMSE, do not apply well in this cohort.
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Combined with the results of the current study, PiB binding in DS frontal cortex appears to 
reflect primarily fibrillar Aβ42 as well as possibly extensive CAA, which may be 
exacerbated in DS (Wilcock, et al., 2016). However, it should be stressed that in vitro, 3H-
PiB binding shows equivalent binding to both Aβ40 and Aβ42 (Klunk, et al., 2005). It may 
also be the case that 3H-PiB binding reflects that there is more Aβ42 than Aβ40 in brain. 
The significant individual variability we observe in DS autopsy studies particularly over 40 
years of age may be due to the presence of dementia or to AD disease severity as suggested 
in a study of sporadic AD (Beckett, et al., 2012) or in disease duration.
We have focused on only the frontal cortex in the current study, which is a limitation given 
that the earliest signs of PET 11C-PiB binding in DS are in the striatum (Annus, et al., 
2016;Handen, et al., 2012;Lao, et al., 2016). In these PET 11C-PiB binding studies, striatal 
binding occurs between 36–40 years of age. A similar study using striatal samples would be 
very interesting in this cohort of at-risk individuals and may reveal an earlier age of onset of 
PiB binding in vitro; it would require more cases between 20–40 years. Unfortunately, we do 
not as yet have frozen samples to make a similar comparison in this brain region. Future 
studies will evaluate both the binding of 3H-PiB in frozen samples and CN-PiB in fixed 
striatal samples with similar hypotheses. We may predict that striatal 3H-PiB would have an 
earlier age of onset of increase in concentration than frontal cortex. It would also be critical 
to determine if PiB is binding only to plaques and CAA in the striatum or if other 
pathological features may be leading to enhanced binding. Ideally, cognitively characterized 
autopsy cases would be included in future studies and may help account for individual 
variability but these cases are a challenge to acquire currently.
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Fig. 1. 
Age-Specific 3H-PiB and 3H-X-34 frontal cortex binding in DS. In DS, the extent of 3H-PiB 
binding in the frontal cortex increased with age, with an exponential increase over the age of 
40 years (A). 3H-X-34 binding was also significantly increased with age (B). This is in 
contrast to 3H-PiB (C) and 3H-X-34 (D) binding in similarly aged control cases showing no 
change as a function of age.
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Fig. 2. 
6-CN-PiB binding in the frontal cortex of DS and control cases. 6-CN-PiB binding was not 
observed in A. a 19-year old control case, B. a 19.8-year old DS case and, C. a 51-year old 
middle aged control case. In contrast, D. shows abundant 6-CN-PiB binding in plaques 
(arrowheads) and in CAA (arrows) in a 51.4 year old person with DS. Bar = 300 μm.
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Fig. 3. 
Double fluorescence labeling for 6-CN-PiB and thioflavine S in DS. (A) In a 51.4 year old 
DS autopsy case, 6-CN-PiB (blue) bound to plaques (arrows) and CAA (arrowheads) and 
could be distinguished from thioflavine S labeling of neurofibrillary tangles (green). (B) A 
higher magnification of a single 6-CN-PiB positive plaque (arrow) shows the presence of 
thioflavine S positive dystrophic neurites (arrowheads) in the periphery suggesting a neuritic 
plaque. (C) In another 6-CN-PiB positive plaque (arrow), fibrils can be seen forming a 
positive core of the plaque, whereas thioflavine S-positive fibrils were associated with the 
periphery (arrow) and were also present in neurofibrillary tangles (arrowheads).
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Table 1
Case demographics
Characteristic DS Control
N 39 25
Mean Age (range) years 44.1 (1–66) 36.4 (1–66)
PMI (hours) 9.6 15.2
Female (%) 20 (59) 10 (40)
Neurobiol Aging. Author manuscript; available in PMC 2018 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
LeVine et al. Page 15
Table 2
Stepwise regression analysis of best predictors for PiB and 3H-X-34binding
Dependent Model R R Square Adjusted R Square
Specific PiB
SDS Aβ42 0.711 0.506 0.499
SDS Aβ42 + Oligomers 0.788 0.621 0.610
SDS Aβ42 + Oligomers + FA Aβ42 0.811 0.658 0.643
Specific 3H-X-34
Oligomers 0.650 0.423 0.414
Oligomers + FA Aβ 40 0.734 0.539 0.525
Oligomers + FA Aβ 40+FA Aβ 42 0.760 0.577 0.558
Neurobiol Aging. Author manuscript; available in PMC 2018 June 01.
